Literature DB >> 7115275

Ultrastructural changes in the human lung following cardiopulmonary bypass.

E Anyanwu, H Dittrich, R Gieseking, H J Enders.   

Abstract

In order to assess the degree of the pathological changes presenting in the lungs of patients after elective cardiac operations in cardiopulmonary bypass and to determine their prognosis, lung biopsies were taken from the right lower lobe of 36 patients after extracorporeal circulation and studied ultrastructurally. Prepump biopsies from the same presenting anterior portion of the lower lobe of the lung served as controls. Perivascular and interstitial edema featured prominently. Intraalveolar edema and extravasated corpuscular blood elements were observed, too. Damages to the mitochondria and to the lamellar bodies and swelling of the endothelial and alveolar cells were major observations following cardiopulmonary bypass lasting more than 60 minutes. These changes were also prominent in those lungs presenting with severe edema and fibrosis. Many intact type-II pneumocytes presented with enhanced metabolic and secretory activities. Merocrine and apocrine secretions were observed after extracorporeal circulation. The alveoli of the postpump lungs contained numerous detached normal appearing type-II pneumocytes, in contrast to the paucity of such cells in the alveoli of the control biopsies. The prognosis for the patients depends on any one or combination of any of the following factors: the pathological changes present in the lungs prior to the extracorporeal circulation, the duration of the cardiopulmonary bypass, the rate of the elimination of the surfactant and finally the ability of the undamaged type-II pneumocytes to step up the synthesis and secretion of the surface acting agent.

Entities:  

Mesh:

Year:  1982        PMID: 7115275     DOI: 10.1007/bf01908046

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  22 in total

1.  The postperfusion pulmonary congestion syndrome.

Authors:  D M BAER; J J OSBORN
Journal:  Am J Clin Pathol       Date:  1960-11       Impact factor: 2.493

2.  The effect of cardiopulmonary bypass on surface activity of lung extracts.

Authors:  R E GARDNER; T N FINLEY; W H TOOLEY
Journal:  Bull Soc Int Chir       Date:  1962 Sep-Oct

3.  Respiratory distress syndrome in the adult after cardiopulmonary bypass. A successful therapeutic approach.

Authors:  R Llamas; H J Forthman
Journal:  JAMA       Date:  1973-09-03       Impact factor: 56.272

4.  Pulmonary changes in cardiopulmonary bypass: short-term effects on granular pneumocytes.

Authors:  R E Sobonya; J Kleinerman; F Primiano; E D Chester
Journal:  Chest       Date:  1972-02       Impact factor: 9.410

5.  Pulmonary injury secondary to extracorporeal circulation. An ultrastructural study.

Authors:  N B Ratliff; W G Young; D B Hackel; E Mikat; J W Wilson
Journal:  J Thorac Cardiovasc Surg       Date:  1973-03       Impact factor: 5.209

6.  Pulmonary complications following extracorporeal circulation.

Authors:  W B Gauert; D S Anderson; W A Reed; A W Templeton
Journal:  South Med J       Date:  1971-06       Impact factor: 0.954

7.  Pulmonary microcirculatory response to shock, transfusion, and pump-oxygenator procedures: a unified mechanism underlying pulmonary damage.

Authors:  F J Veith; J W Hagstrom; A Panossian; S L Nehlsen; J W Wilson
Journal:  Surgery       Date:  1968-07       Impact factor: 3.982

8.  The lung in hemorrhagic shock. II. Observations on alveolar and vascular ultrastructure.

Authors:  N B Ratliff; J W Wilson; D B Hackel; A M Martin
Journal:  Am J Pathol       Date:  1970-02       Impact factor: 4.307

9.  Pulmonary complications following perfusion of the lungs.

Authors:  J A Awad; J M Lemieux; W Lou
Journal:  J Thorac Cardiovasc Surg       Date:  1966-06       Impact factor: 5.209

10.  Postoperative pulmonary patterns following cardiopulmonary bypass.

Authors:  A W Templeton; C H Almond; A Seaber; C Simmons; J MacKenzie
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1966-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.